Market News & Trends
Kintai Therapeutics Announces Collaborations With Leading Academic Centers
Kintai Therapeutics recently announced it has established new collaborations with leading academic institutions to identify novel molecules that play a fundamental role in microbe to…
PCI Strengthens Position in Europe With Investment in Ireland
PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has solidified its leadership position in the EU with strategic investment to deepen its presence…
Adaptimmune & Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products
Adaptimmune Therapeutics plc and Noile-Immune Biotech, Inc. recently announced they will co-develop next-generation SPEAR T-cell products, incorporating Noile-Immune’s PRIME (proliferation inducing and migration enhancing) technology,…
Ivy Brain Tumor Center & Salarius Pharmaceuticals Launch Collaborative Partnership
The Ivy Brain Tumor Center at the Barrow Neurological Institute and Salarius Pharmaceuticals, Inc. recently announced a collaborative partnership to test Salarius’ therapeutic candidate, Seclidemstat,…
Aptinyx Presents Data Demonstrating Positive Activity on Cognitive Performance & Biomarkers in a Preclinical Model
Aptinyx Inc. recently announced the presentation of preclinical data on its novel NMDA receptor modulator, NYX-458. The product candidate demonstrated positive recovery of performance on…
Landos Biopharma Announces First Patient Dosed in Global Phase 2 Clinical Trial
Landos Biopharma, Inc. recently announced dosing of the first patient in a Phase 2 study evaluating the safety and efficacy of BT-11 in patients with…
MyoKardia Begins Dosing in Phase 1 Clinical Study
MyoKardia, Inc. recently announced it has dosed the first subjects in a Phase 1 clinical study of MYK-224, a small molecule candidate being developed for…
Outlook Therapeutics Completes Patient Enrollment for Phase 3 Clinical Trial
Outlook Therapeutics, Inc. recently announced that it has completed patient enrollment in the NORSE 1 Phase 3 clinical trial, which is evaluating ONS-5010 against ranibizumab…
Altimmune Announces $3.7 Million in Additional BARDA Funding
Altimmune, Inc. recently announced the Biomedical Advanced Research and Development Authority (BARDA) is modifying its existing anthrax vaccine development contract with Altimmune by awarding an…
Innovate Biopharmaceuticals Announces First Patient Dosed in the First Phase 3 Clinical Trial
Innovate Biopharmaceuticals, Inc. recently announced it has dosed the first patient in its Phase 3 clinical trial, CeD LA 3001. This marks the first time…
EXCLUSIVE ONLINE CONTENT
Molex Expands European Manufacturing Footprint & Capabilities With State-of-the-Art Campus in Poland
Molex recently announced a major expansion of its global manufacturing footprint with the opening of a new campus in Katowice, Poland. The facility’s initial 23,000-square-meter manufacturing space will….
Kala Pharmaceuticals Completes Sale of EYSUVIS & INVELTYS to Alcon Inc
Kala Pharmaceuticals, Inc. recently announced it has completed the sale of its commercial portfolio and related intellectual property assets to Alcon Inc., a transaction that was….
Insightful Science Acquires Protein Metrics to Expand its R&D Solution to Include Proteomics
Insightful Science recently announced it has completed the transaction to acquire Protein Metrics, Inc. to expand the company’s R&D value chain to widen the biopharmaceutical protein analysis arena….
Acer Therapeutics & Relief Therapeutics Announce NDA Submission for ACER-001 for Treatment of Urea Cycle Disorders
Acer Therapeutics Inc. Relief Therapeutics recently announced the submission of a New Drug Application (NDA) to the US FDA for ACER-001 (sodium phenylbutyrate) for the treatment of Urea Cycle Disorders (UCDs)….